Health & Research Goals
NAD+ (Nicotinamide Adenine Dinucleotide)
NAD+ (Nicotinamida Adenina Dinucleótido)
Nicotinamide adenine dinucleotide (NAD+) is not a peptide but a coenzyme found in every living cell, essential for energy metaboli…
Primary Description
Nicotinamide adenine dinucleotide (NAD+) is not a peptide but a coenzyme found in every living cell, essential for energy metabolism, DNA repair, sirtuin activation, and cellular survival. NAD+ levels decline approximately 60% from early to late adulthood across multiple tissues, and this decline is closely linked to hallmarks of aging including metabolic dysfunction, cognitive decline, and reduced cellular repair capacity. The biohacker and longevity community uses injectable NAD+ (subcutaneous or IV) as well as oral precursors NMN and NR, with debate ongoing about whether direct injection vs. oral precursors more effectively raises intracellular NAD+ levels. Community uses span energy/performance, cognitive function, longevity, and a well-documented application in alcohol and substance use recovery (the BR+NAD protocol).
Key Benefits
- Sirtuin (SIRT1–7) activation → epigenetic anti-aging effects
- Mitochondrial bioenergetics — NAD+/NADH ratio restoration
- DNA repair acceleration via PARP enzyme support
- Cognitive clarity and neuroprotection
Highly sensitive to degradation. Lyophilized powder: store at -20C in airtight container. Reconstituted solution: refrigerate at 2-8C, use within 30 days, discard if discolored. Do not expose to heat, light, or oxidizing conditions. IV-grade NAD+ requires pharmaceutical-grade preparation from compounding pharmacy.
Demonstrated Effects
- Restoration of age-related NAD+ decline — replenishes systemic coenzyme levels that fall ~60% from youth to older age
- Sirtuin (SIRT1-7) activation — the NAD+-dependent longevity enzyme family driving DNA repair, inflammation regulation, and mitochondrial quality control
- Enhanced cellular energy production via NADH/NAD+ redox cycling in glycolysis and the TCA cycle
- DNA repair support via PARP enzyme activation (NAD+ is the exclusive PARP substrate)
- Cognitive function and neuroprotection — SIRT1-mediated neuroprotection, PARP-dependent neuronal DNA repair, axonal integrity maintenance
- Mitochondrial biogenesis and function via PGC-1alpha/SIRT1 axis
- Substance use and addiction recovery support (BR+NAD protocol: 500-1000 mg IV, well-documented in addiction medicine)
- Anti-inflammatory effects via modulation of NF-kB and SIRT1 pathways
Proposed Mechanisms of Action
1. Sirtuin (SIRT1-7) Activation
NAD+ is the exclusive co-substrate for all 7 sirtuin deacylase enzymes. When NAD+ levels are high, sirtuins are active — deacetylating and regulating a vast range of target proteins involved in gene expression, DNA repair, mitochondrial quality, inflammation, and circadian rhythms.
Core longevity and anti-aging mechanism. SIRT1 regulates hundreds of genes; SIRT3 maintains mitochondrial function; SIRT6 is critical for DNA damage repair.
2. PARP Enzyme Activation (DNA Repair)
Poly(ADP-ribose) polymerases (PARPs) use NAD+ as their sole substrate to catalyze poly-ADP-ribosylation, a critical modification for DNA damage sensing and repair. PARP overactivation in response to high DNA damage depletes NAD+ rapidly.
Explains why NAD+ supplementation can improve DNA repair capacity, and why conditions with high oxidative stress (aging, substance use) deplete NAD+ and benefit most from replenishment.
3. Cellular Energy Metabolism (Redox Cycling)
NAD+ and NADH form a redox pair central to glycolysis, the TCA cycle, and oxidative phosphorylation. The NAD+/NADH ratio acts as a metabolic sensor that regulates the activity of metabolic enzymes and communicates cellular energy status.
Direct driver of cellular ATP production. Declining NAD+/NADH ratios in aging cells impair energy metabolism and are a root cause of age-related metabolic dysfunction.
Research Evidence & Clinical Data
Investigated Applications
Longevity / Cellular Anti-Aging
Anecdotal: HighCore use case in the longevity community. Community members report improved energy, better recovery, enhanced cognitive clarity, and improved sleep quality. Oral NMN/NR precursors are the most accessible approach; injectable NAD+ is used for more acute or intensive effects.
Preclinical basis: Oral NR 1000 mg/day raises NAD+ in PBMCs by ~60% at 6 weeks. NMN + NR extend lifespan up to 30% in invertebrates. Multiple human trials confirm precursor safety and NAD+ elevation.
Cognitive Function / Neuroprotection
Anecdotal: HighCommunity widely reports enhanced mental clarity, focus, and reduced brain fog with NAD+ supplementation. IV NAD+ infusions are particularly described as producing rapid (same-day) cognitive sharpening. Useful for high cognitive demand periods.
Preclinical basis: NAD+ precursors improve cognition in Alzheimer's disease models. SIRT1 activation protects neurons from oxidative stress. Systematic review confirms neuroprotective and pro-cognitive effects in preclinical AD models.
Addiction and Substance Use Recovery
Anecdotal: HighThe BR+NAD (Brain Restoration + NAD) protocol uses high-dose IV NAD+ (500-1000 mg daily for 10-15 days) as part of an addiction recovery protocol. Clinicians and community members report reduced withdrawal severity, decreased cravings, and improved mood during substance use recovery.
Preclinical basis: NAD+ depletion is associated with addiction vulnerability. Restoring NAD+ supports dopaminergic signaling normalization and mitochondrial energy production in neurons affected by substance use.
Energy and Athletic Performance
Anecdotal: ModerateCommunity athletes and biohackers report enhanced energy, endurance, and recovery. Effects may be more pronounced in older individuals with lower baseline NAD+ levels.
Preclinical basis: NMN supplementation improved muscle function and reduced insulin resistance in middle-aged adults (meta-analysis 2024). NAD+ is required for ATP production in all cells including contracting muscle.
Scientific References
- 1.Yoshino et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic womenScience2021
First randomized trial showing NMN 250 mg/day for 10 weeks improved muscle insulin sensitivity in postmenopausal prediabetic women, confirming human clinical benefit.
- 2.Frontiers in Aging (2026). Intravenous infusion of NAD+ versus nicotinamide riboside: a retrospective tolerability pilot studyFrontiers in Aging2026
Real-world comparison of IV NAD+ vs. IV NR tolerability in clinic patients; informs route selection and infusion rate optimization.
- 3.
- 4.Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future DirectionsJ Gerontol A Biol Sci Med Sci2023
- 5.
- 6.
- 7.NAD(+) metabolism and its roles in cellular processes during ageingNat Rev Mol Cell Biol2021
Safety Profile
Common Side Effects
- IV: Flushing, warmth, nausea, headache, chest tightness (dose-rate dependent — slower infusion dramatically reduces severity)
- SubQ: Injection site stinging, burning, erythema, small nodules
- Nausea and abdominal discomfort (especially with high IV doses)
- Fatigue or brain fog during initial titration (may represent cellular adaptation)
- Headache
- Muscle pain (reported in some clinical trial participants)
- Diarrhea (higher oral NMN/NR doses)
Contraindications
- Known allergy or hypersensitivity to NAD+ or its components
- Severe hepatic impairment (metabolism primarily hepatic)
- Severe renal impairment (clearance affected)
- Cardiovascular disease or bleeding disorders — IV infusion only; SubQ and oral lower risk
- Active cancer — NAD+ is required for cancer cell proliferation; theoretical concern of supporting tumor growth; consult oncologist
- Pregnancy and breastfeeding — no safety data
Pre-Use Screening Checklist
NAD+ is required by both cancer and healthy cells. Some oncologists support NAD+ supplementation; others advise caution pending more data on whether NAD+ supplementation supports tumor growth.
IV NAD+ causes transient blood pressure and vascular changes via GPR109A activation (niacin-like flush). Consult cardiologist before IV protocols. SubQ and oral are lower risk.
Whole blood NAD+ testing (available commercially) allows quantification of baseline deficit and objective tracking of protocol efficacy. High variability in baseline levels makes testing useful.
Legal & Regulatory Status
Not FDA-approved as a drug or supplement for any specific indication. NAD+ therapy is not FDA-approved. NMN's status as a dietary supplement was challenged by the FDA (2022 exclusion from supplement category), but the FDA reversed the exclusion in 2024. Direct injectable NAD+ requires compounding pharmacy preparation.
Not listed on WADA Prohibited List. NAD+, NMN, and NR are not classified as prohibited substances in competitive sport.
Not approved by COFEPRIS as a drug. Injectable NAD+ available through compounding pharmacies in Mexico. Oral NMN/NR available as supplements.
Not approved by EMA as a drug. NMN/NR sold as food supplements in many EU countries. Injectable preparation requires medical compounding.
TGA does not regulate injectable NAD+ as a listed therapeutic good. Available through authorized compounding pharmacies under prescribing physician supervision.
Research Protocols
Dosing Protocols
SubQ home protocol — energy, longevity, cognitive
Subcutaneous (back of arm, abdomen, or thigh at 45-degree angle)IV infusion — clinic protocol (acute cognitive or recovery)
Intravenous infusion (clinic setting only, infuse slowly over 2-8 hours to minimize flush/nausea)Oral NMN/NR precursor — daily maintenance
OralRoutes of Administration
Subcutaneous injection
Most commonSelf-administered at home using insulin syringe. Injected at 45 degrees into abdominal, thigh, or upper arm subcutaneous fat. Allows regular dosing without clinic visits.
Injection site stinging/burning is common — particularly at higher concentrations. Diluting to lower concentration reduces local irritation. Massage site gently post-injection.
Intravenous infusion
Specific useHighest bioavailability (100%). Requires clinical setting. Used for acute cognitive enhancement, addiction recovery protocols, and intensive longevity protocols. Produces strongest and most immediate effects.
Must be infused slowly (2-8 hours) to minimize nausea, flushing, chest tightness. Typical clinic protocol: 250 mg over 2-3 hours. 500+ mg requires 4-8 hours.
Oral (NMN / NR precursors)
Most commonDaily oral NMN or NR supplementation is the most accessible and widely studied approach. Precursors are converted to NAD+ intracellularly and are arguably more efficient at raising intracellular NAD+ than direct NAD+ injection (which may be hydrolyzed extracellularly).
Take NMN on empty stomach in the morning. NR is well absorbed with or without food. Pharmaceutical-grade, third-party tested products recommended. Retest blood NAD+ levels after 6-8 weeks to confirm protocol efficacy.
Reconstitution Guide
Sterile saline (0.9% NaCl) or bacteriostatic water depending on preparation. IV-grade NAD+ is typically supplied as a lyophilized powder for reconstitution in sterile saline.
1. Compounding pharmacy prepares IV or SubQ grade NAD+ under aseptic conditions. 2. For SubQ: reconstitute lyophilized powder with bacteriostatic water per pharmacy directions. 3. Gently swirl to dissolve. 4. Inspect for clarity — discard if cloudy or particulate.
For SubQ: 200 mg vial + 2 mL bacteriostatic water = 100 mg/mL. A 100 mg dose = 1 mL. For IV: 500 mg vial reconstituted and diluted into 250 mL sterile saline for slow infusion.
Refrigerate at 2-8C. Use within 30 days. Discard if color change or cloudiness noted. NAD+ is susceptible to oxidation — minimize air exposure.
Store at -20C, airtight, desiccated, protected from light. Extremely sensitive to moisture and oxidation in powder form.
Oral NMN/NR: morning on empty stomach for optimal absorption. SubQ: morning preferred; some community members use on training days. IV: clinic scheduling dependent — morning sessions allow full-day benefit.
Pharmacokinetics
| Half-Life | Direct NAD+ injected IV is rapidly converted to nicotinamide in plasma (half-life minutes to under 1 hour for intact NAD+). Oral NMN and NR have half-lives of 1-4 hours in plasma but raise intracellular NAD+ levels sustainably over days with repeated dosing. |
| Absorption | IV: 100% bioavailability. SubQ: high absorption from subcutaneous tissue, absorbed into systemic circulation. Oral NMN/NR: 20-50% absorption depending on form and food; converted intracellularly to NAD+ after cell uptake. |
| Distribution | NAD+ does not cross cell membranes directly — must be hydrolyzed to precursors (NMN, NR, Nam) that enter cells and are re-synthesized intracellularly. Distribution to all tissues through precursor form. |
| Metabolism | Injectable NAD+ is rapidly hydrolyzed to nicotinamide (Nam) in plasma by CD38 and other ectoenzymes. Nam enters cells and is recycled to NAD+ via the salvage pathway (NAMPT enzyme). This extracellular hydrolysis is why some researchers favor oral precursors over direct NAD+ injection for intracellular elevation. |
| Molecular Structure | Dinucleotide consisting of adenosine monophosphate and nicotinamide mononucleotide joined by a pyrophosphate bond. MW 663.43 g/mol. CAS 53-84-9. Reduced form is NADH. |
Monitoring & Risk Management
Ongoing Monitoring Steps
- Blood NAD+ levelsConfirm protocol is raising NAD+ above baseline. Adjust dose or route if levels not improving.Check: Every 6-8 weeks
- Liver function testsNAD+ metabolism is primarily hepatic. Monitor ALT/AST in high-dose IV protocols.Check: Every 3-6 months with high-dose supplementation
- Subjective cognitive and energy markersTrack energy levels, cognitive clarity, sleep quality, and exercise capacity against baseline journal notes.Check: Monthly
Critical Warning Signs
- Chest tightness, difficulty breathing, or palpitations during IV infusionStop infusion immediately. These symptoms usually reflect infusion rate being too fast. Slow the rate or discontinue. Monitor for cardiovascular event. If symptoms persist after stopping, seek emergency care.Urgency: IMMEDIATE
- Severe persistent nausea/vomiting after SubQ injectionReduce dose and concentration. Ensure injection technique is correct (no IV inadvertent injection). Consider switching to oral NMN/NR if SubQ is poorly tolerated.Urgency: Within 24-48 hours
- Unexplained fatigue, jaundice, or right upper quadrant painDiscontinue and obtain liver function tests. May indicate hepatic stress from high-dose NAD+ metabolism.Urgency: Within 24-48 hours
Featured in Stacking Protocols
Community-researched combinations involving this compound
Resveratrol / Pterostilbene
Sinclair Longevity StackMaximize sirtuin activation by combining NAD+ substrate (NMN) with SIRT1 activator (resveratrol)
NMN raises NAD+ levels; resveratrol activates SIRT1 which consumes NAD+. Together they create a synergistic increase in sirtuin activity exceeding either alone. Co-administration increases NAD+ in heart and skeletal muscle 1.6-1.7x more than NMN alone.
NMN 500 mg oral in the morning empty stomach + Resveratrol 500 mg with a fatty meal + TMG 500 mg for methylation support. Daily protocol.
MOTS-C
Mitochondrial Longevity StackMOTS-C modulates NAD+/NADH ratio and activates AMPK; NAD+ provides substrate for MOTS-C-driven sirtuin activity
Complementary mitochondrial support — MOTS-C provides signaling (AMPK, nuclear retrograde signaling); NAD+ provides the metabolic substrate for longevity enzymes. Theoretically the most mechanistically complete mitochondrial support stack.
MOTS-C 5 mg SubQ 2-3x weekly + NMN 500 mg oral daily + Resveratrol 500 mg with fat.
Metformin
Metabolic Optimization StackAMPK activation (metformin) combined with NAD+-mediated sirtuin activation for comprehensive longevity signaling
Metformin activates AMPK by complex I inhibition; this increases NAD+ demand. Community uses NAD+ supplementation to ensure adequate substrate for the AMPK-driven sirtuin activation metformin promotes.
Metformin 500-1000 mg daily with meals + NMN 500 mg oral morning. Rapamycin sometimes added for mTOR inhibition in advanced longevity protocols.
CoQ10
Mitochondrial Energy StackCombine NAD+ electron transport chain support with CoQ10 which is also essential for mitochondrial electron transfer
NAD+/NADH and CoQ10 are sequential electron carriers in the mitochondrial electron transport chain. Combined supplementation addresses multiple steps in ATP production. Combining NMN + resveratrol + CoQ10 raises NAD+ 1.6-1.7x more than NMN alone.
NMN 500 mg + CoQ10 200-400 mg (ubiquinol form preferred) with a fatty meal. Daily.